1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

  • August 2016
  • ID: 4100753
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Global Diabetes and Obesity Drugs Market to 2022 - Insulins and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment

Summary

Diabetes mellitus refers to a group of metabolic diseases characterized by chronic hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both of these (ADA, 2014). Under normal circumstances insulin is secreted by the pancreas and into the blood stream upon digestion of food, and subsequent absorption of glucose into the bloodstream. Here it acts to facilitate the absorption of glucose by target cells.

The pipeline for the disease cluster of diabetes and obesity is strong, with a notable rise in revenues expected over the forecast period, despite patent expiries for a number of key marketed drugs. The global market size for this disease cluster is anticipated to grow considerably over the forecast period, from USD70.8 Billion in 2015 to USD163.2 Billion in 2022, at a compound annual growth rate (CAGR) of 12.7%.

The growth of the disease cluster is driven not only by the rising global incidence of obesity, but also the subsequent effect that this has on T2DM incidence, given the intrinsic link between the two diseases. Furthermore, many products indicated for obesity are also indicated for T2DM, as combating obesity in T2DM patients improves diabetic symptoms, and it is these multiple-indication products that produce the greatest revenues and show the most promise as key future therapeutics.

According to Callum Dew, GBI Research, explains: “Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide). The disease cluster is dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and T2DM, and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications.”

An increasing pipeline presence for obesity-indicated products and overwhelming global media interest highlight the relevance of this indication and its future potential global revenues. However, the number of pharmacotherapeutic products and revenues for obesity are dwarfed by diabetes-indicated products. Given the status of obesity as a risk factor for T2DM, it is likely that the T2DM market will continue to rise with the rising obesity incidence.

The report “Global Diabetes and Obesity Drugs Market to 2022 - Insulin’s and GPCRs Retain Commercial Prominence, While High Unmet Need Remains in Weight Loss Treatment” provides an introduction to the disease cluster of diabetes and obesity, and some detailed background information regarding the diseases. Information is also included regarding symptoms, etiology and pathophysiology, comorbidities and epidemiology.

In depth, it provides the following analysis -
- Provides an overview of the marketed products of diabetes and obesity, including product profiles of key marketed products, and revenue projections for each of these drugs.
- Helps to analyze the diabetes and obesity pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus separate analysis of T1DM, T2DM and obesity.
- Provides forecast projections to 2022 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players.
- Assesses the company landscape for the disease cluster, with an analysis of the key players, the types of company involved, and whether the disease cluster comprises a large proportion of each company’s pipeline portfolio and total revenues.
- Analyses of trends in co-development and licensing deals relating to diabetes and obesity products. Some of the most prominent deals are discussed in detail.

Companies mentioned in this report: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co, AstraZeneca, Takeda,

Scope

- What are the current treatment options for diabetes and obesity?
- What are the common molecular targets of pipeline therapies, and how strongly do they overlap with the current market?
- Will the pipeline address unmet needs such as a lack of safe treatment options for diabetes and obesity patients?
- Which late-stage pipeline products are likely to impact the current market?
- How are revenues of key companies, targets and molecule types anticipated to change over the forecast period?
- Which companies are anticipated to be the most prominent players over the next seven years?
- How do licensing and co-development deals compare between diabetes and obesity?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the diabetes and obesity market in terms of the clinical and commercial standing of current dominant therapies. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the diabetes and obesity pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There is a strong contrast in the amount of pipeline activity for diabetes and obesity.
- Analyze how individual company, molecule type and molecular target revenues are anticipated to change over the forecast period, highlighting prominent companies and the most promising molecule types and targets.
- Identify which companies are the current key players for the disease cluster, and how this pattern is anticipated to change over the forecast period.
- Identify commercial opportunities in the diabetes and obesity deals landscape by analyzing trends in licensing and co-development deals by stage of development, molecule type and molecular target.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

  • $ 2500
  • April 2021
  • 218 pages

KEY FINDINGS The global non-alcoholic steatohepatitis (NASH) biomarker market is projected to grow with a CAGR of 20.65%, over the forecast period of 2021 to 2028. The market growth is mainly accredited ...

  • World
  • APAC
  • Obesity
  • Hepatitis
  • Industry analysis
  • Overweight Prevalence
  • Diabetes Prevalence

ref:plp2016

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on